AGIO
AGIO
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
53
$10.88M
Total Volume
$10.88M
53 transactions
Net Activity
$10.88M
Net selling
Sentiment Rating
Heavy DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Goff Brian
CEO
$3.19M total
Gheuens Sarah
Chief Medical Officer
$2.53M total
Burns James William
GC
$1.72M total
Ballal Rahul D.
Dir
$1.12M total
Washburn Theodore James Jr.
Principal Accounting Officer
$648K total
Quick Actions
AGIO has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at AGIO (AGIO) engaged in a total of 53 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 53 were sales. The total volume of insider trading reached $10.88M.
The net insider activity for AGIO shows a net selling bias of $10.88M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Burns James William (GC), who traded 21.8K shares valued at $1.14M on Nov 7, 2024.
Agios Pharmaceuticals (AGIO) Stock Looks Pricey Despite Its 39% Run
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
Agios falls on review extension for Pyrukynd label expansion
AGIO - Agios Pharmaceuticals Inc Stock Price and Quote
Agios Pharmaceuticals (AGIO) Stock Looks Fully Priced Against Current Sales
Agios Pharmaceuticals Stock (AGIO) Opinions on Trading Strategies | AGIO Stock News
FAQs About AGIO Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for AGIO.